Compass Therapeutics, Inc.

Healthcare · Biotechnology · United States

Last price 0.7698 USD (Oct 30, 2026, 3:19 PM EDT) · Market cap 138.63M

Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports

Compass Therapeutics, Inc., a clinical-stage oncology-focused biopharmaceutical company, develops antibody-based therapeutics for the treatment of various human diseases in the United States. The company’s lead product candidate, tovecimig, is a bispecific antibody that targets delta-like ligand 4 (DLL4) and vascular endothelial growth factor A (VEGF-A), which are critical to angiogenesis and tumor vascularization. It also develops CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells; C...